Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Increased capability to produce medicines for challenging diseases including cancer
Lokavant provides clinical trial intelligence
Tolvaptan Tablets (RLD Jynarque) had estimated annual sales of USD 287 million in the U.S. (IQVIA MAT August 2023)
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
The approval adds to a list of products that Strides has approved in this therapeutic category through the PEPFAR pathway taking the total to 15 products
His M&A background and experience with successful private-equity-backed companies will benefit the company’s growth and diversification strategy
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
The product is bioequivalent and therapeutically equivalent to the RLD, Vascepa of Amarin
Subscribe To Our Newsletter & Stay Updated
